PRESS RELEASE

Q4 2024 — Press release

Q4 2024PDF · 22 pages1.6 MB
For immediate release

-- 1 of 22 --



-- 2 of 22 --

2.0% – 3.0% / 2.5%
$90.9B – $91.7B / $91.3B
2.5% – 3.5% / 3.0%
$89.2B – $90.0B / $89.6B
0.5% – 1.5% / 1.0%
$10.75 – $10.95 / $10.85
7.7% – 9.7% / 8.7%
$10.50 – $10.70 / $10.60
5.2% – 7.2% / 6.2%

-- 3 of 22 --



-- 4 of 22 --



-- 5 of 22 --



-- 6 of 22 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2024 2023 Total Operations Currency 2024 2023 Total Operations Currency
Sales to customers by
segment of business
Innovative Medicine (1)
U.S. 8,977	$ 8,079 11.1 % 11.1 - 33,970	$ 31,169 9.0 % 9.0 -
International 5,355 5,643 (5.1) (1.0) (4.1) 22,994 23,590 (2.5) 1.3 (3.8)
14,332 13,722 4.4 6.1 (1.7) 56,964 54,759 4.0 5.7 (1.7)
Innovative Medicine excluding COVID-19 Vaccine (1)
U.S. 8,977 8,079 11.1 11.1 - 33,970 31,169 9.0 9.0 -
International 5,355 5,599 (4.4) (0.3) (4.1) 22,796 22,473 1.4 5.5 (4.1)
14,332 13,678 4.8 6.5 (1.7) 56,766 53,642 5.8 7.5 (1.7)
MedTech
U.S. 4,227 3,930 7.6 7.6 - 16,332 15,275 6.9 6.9 -
International 3,961 3,743 5.8 7.6 (1.8) 15,525 15,125 2.6 5.4 (2.8)
8,188 7,673 6.7 7.6 (0.9) 31,857 30,400 4.8 6.2 (1.4)
U.S. 13,204 12,009 10.0 10.0 - 50,302 46,444 8.3 8.3 -
International 9,316 9,386 (0.7) 2.5 (3.2) 38,519 38,715 (0.5) 2.9 (3.4)
Worldwide 22,520 21,395 5.3 6.7 (1.4) 88,821 85,159 4.3 5.9 (1.6)
U.S. 13,204 12,009 10.0 10.0 - 50,302 46,444 8.3 8.3 -
International 9,316 9,342 (0.3) 2.9 (3.2) 38,321 37,598 1.9 5.5 (3.6)
Worldwide excluding COVID-19 Vaccine (1) 22,520	$ 21,351 5.5 % 6.9 (1.4) 88,623	$ 84,042 5.5 % 7.0 (1.5)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Refer to supplemental sales information schedules
FOURTH QUARTER TWELVE MONTHS
Percent Change

-- 7 of 22 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2024 2023 Total Operations Currency 2024 2023 Total Operations Currency
Sales to customers by
geographic area
U.S. 13,204	$ 12,009 10.0 % 10.0 - 50,302	$ 46,444 8.3 % 8.3 -
Europe 4,921 4,962 (0.8) (0.2) (0.6) 20,212 20,410 (1.0) (0.6) (0.4)
Western Hemisphere excluding U.S. 1,135 1,166 (2.7) 17.6 (20.3) 4,714 4,549 3.6 20.4 (16.8)
Asia-Pacific, Africa 3,260 3,258 0.1 0.9 (0.8) 13,593 13,756 (1.2) 2.3 (3.5)
International 9,316 9,386 (0.7) 2.5 (3.2) 38,519 38,715 (0.5) 2.9 (3.4)
Worldwide 22,520	$ 21,395 5.3 % 6.7 (1.4) 88,821	$ 85,159 4.3 % 5.9 (1.6)
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2024 2023 Total Operations Currency 2024 2023 Total Operations Currency
Sales to customers by
geographic area (ex. COVID-19 Vaccine)
U.S.* 13,204	$ 12,009 10.0 % 10.0 - 50,302	$ 46,444 8.3 % 8.3 -
Europe(1) 4,921 4,918 0.1 0.7 (0.6) 20,014 19,293 3.7 4.1 (0.4)
Western Hemisphere excluding U.S.* 1,135 1,166 (2.7) 17.6 (20.3) 4,714 4,549 3.6 20.4 (16.8)
Asia-Pacific, Africa* 3,260 3,258 0.1 0.9 (0.8) 13,593 13,756 (1.2) 2.3 (3.5)
International 9,316 9,342 (0.3) 2.9 (3.2) 38,321 37,598 1.9 5.5 (3.6)
Worldwide 22,520	$ 21,351 5.5 % 6.9 (1.4) 88,623	$ 84,042 5.5 % 7.0 (1.5)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Refer to supplemental sales information schedules
*No COVID-19 Vaccine sales
Percent Change
FOURTH QUARTER TWELVE MONTHS
Percent Change
FOURTH QUARTER TWELVE MONTHS

-- 8 of 22 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 22,520	$ 100.0 21,395	$ 100.0 5.3
Cost of products sold 7,128 31.6 6,798 31.8 4.9
Gross Profit 15,392 68.4 14,597 68.2 5.4
Selling, marketing and administrative expenses 6,453 28.6 5,810 27.1 11.1
Research and development expense 5,298 23.5 4,480 20.9 18.3
In-process research and development impairments 17 0.1 58 0.3
Interest (income) expense, net (144) (0.6) (212) (1.0)
Other (income) expense, net (161) (0.7) (421) (2.0)
Restructuring 42 0.2 56 0.3
Earnings before provision for taxes on income 3,887 17.3 4,826 22.6 (19.5)
Provision for taxes on income 456 2.1 694 3.3 (34.3)
Net earnings from Continuing Operations 3,431	$ 15.2 4,132	$ 19.3 (17.0)
Net earnings/(loss) from Discontinued Operations, net of tax - (83)
Net earnings 3,431	$ 4,049	$
Net earnings per share (Diluted) from Continuing Operations 1.41	$ 1.70	$ (17.1)
Net earnings/(loss) per share (Basic) from Discontinued Operations* -	$ (0.03)	$
Average shares outstanding (Diluted) 2,427.1 2,430.7
Effective tax rate from Continuing Operations 11.7 % 14.4 %
Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1)
Earnings before provision for taxes on income from Continuing Operations 5,421	$ 24.1 6,237	$ 29.2 (13.1)
Net earnings from Continuing Operations 4,946	$ 22.0 5,562	$ 26.0 (11.1)
Net earnings per share (Diluted) from Continuing Operations 2.04	$ 2.29	$ (10.9)
Effective tax rate from Continuing Operations 8.8 % 10.8 %
* Basic shares of 2,407.2 are used to calculate loss per share in the fourth quarter of 2023 as use of diluted shares when in a loss position would be anti-dilutive.
(1) See Reconciliation of Non-GAAP Financial Measures.
FOURTH QUARTER
2024 2023

-- 9 of 22 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 88,821	$ 100.0 85,159	$ 100.0 4.3
Cost of products sold 27,471 30.9 26,553 31.2 3.5
Gross Profit 61,350 69.1 58,606 68.8 4.7
Selling, marketing and administrative expenses 22,869 25.7 21,512 25.2 6.3
Research and development expense 17,232 19.4 15,085 17.7 14.2
In-process research and development impairments 211 0.2 313 0.4
Interest (income) expense, net (577) (0.6) (489) (0.6)
Other (income) expense, net 4,694 5.3 6,634 7.8
Restructuring 234 0.3 489 0.6
Earnings before provision for taxes on income 16,687 18.8 15,062 17.7 10.8
Provision for taxes on income 2,621 3.0 1,736 2.1 51.0
Net earnings from Continuing Operations 14,066	$ 15.8 13,326	$ 15.6 5.6
Net earnings from Discontinued Operations, net of tax - 21,827
Net earnings 14,066	$ 35,153	$
Net earnings per share (Diluted) from Continuing Operations 5.79	$ 5.20	$ 11.3
Net earnings per share (Diluted) from Discontinued Operations -	$ 8.52	$
Average shares outstanding (Diluted) 2,429.4 2,560.4
Effective tax rate from Continuing Operations 15.7 % 11.5 %
Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1)
Earnings before provision for taxes on income from Continuing Operations 28,979	$ 32.6 29,811	$ 35.0 (2.8)
Net earnings from Continuing Operations 24,242	$ 27.3 25,409	$ 29.8 (4.6)
Net earnings per share (Diluted) from Continuing Operations 9.98	$ 9.92	$ 0.6
Effective tax rate from Continuing Operations 16.3 % 14.8 %
(1) See Reconciliation of Non-GAAP Financial Measures.
TWELVE MONTHS
2024 2023

-- 10 of 22 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 2024 2023 2024 2023
Net Earnings from Continuing Operations, after tax- as reported $3,431 $4,132 $14,066 $13,326
Pre-tax Adjustments
Litigation related (16) 166 5,450 7,152
Intangible Asset Amortization expense 1,171 1,148 4,526 4,532
COVID-19 Vaccine related costs 1 23 10 100 663
Restructuring related 2 62 139 269 798
Medical Device Regulation 3 47 88 204 311
Acquisition, integration and divestiture related 298 237 1,226 339
(Gains)/losses on securities (68) (435) 306 641
IPR&D impairments 17 58 211 313
Tax Adjustments
Tax impact on special item adjustments 4 (80) 75 (2,135) (2,694)
Tax legislation and other tax related 61 (56) 19 28
Adjusted Net Earnings from Continuing Operations, after tax $4,946 $5,562 $24,242 $25,409
Average shares outstanding (Diluted) 2,427.1 2,430.7 2,429.4 2,560.4
Adjusted net earnings per share from Continuing Operations (Diluted) $2.04 $2.29 $9.98 $9.92
Operational adjusted net earnings per share from Continuing Operations (Diluted) $2.05 $9.99
Notes:
1 COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing
network exit costs and required clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine
contractual commitments which was completed in Q4 2024.
2
3
4 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in
arriving at adjusted earnings.
Fourth Quarter Twelve Months Ended
In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to
focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas.
The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult
vaccine program, hepatitis and HIV development. The restructuring expense of $102 million Q4 2024 YTD and $55 million in the fiscal fourth quarter
of 2023 ($479 million Q4 2023 YTD) includes the termination of partnered and non-partnered program costs, asset impairments and asset
divestments. This program was completed in Q4 2024.
In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by
exiting certain markets, product lines and distribution network arrangements. The restructuring expense of $60 million in the fiscal fourth quarter of
2024 ($167 million Q4 2024 YTD) and $84 million in the fiscal fourth quarter of 2023 ($319 million Q4 2023 YTD) primarily includes costs related to
the market and product exits.
replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were
required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory
change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its
MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance. The implementation was
substantially completed as of Q4 2024, and ongoing costs will be reflected in MedTech's operating results beginning in 2025.

-- 11 of 22 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine MedTech Total
WW As Reported 4.4% 6.7% 5.3%
U.S. 11.1% 7.6% 10.0%
International (5.1)% 5.8% (0.7)%
WW Currency (1.7) (0.9) (1.4)
U.S. - - -
International (4.1) (1.8) (3.2)
WW Operational 6.1% 7.6% 6.7%
U.S. 11.1% 7.6% 10.0%
International (1.0)% 7.6% 2.5%
Shockwave (3.4) (1.2)
U.S. (5.1) (1.7)
International (1.5) (0.6)
All Other Acquisitions and Divestitures (A&D) 0.2 0.4 0.2
U.S. 0.1 0.8 0.3
International 0.3 0.0 0.1
WW Adjusted Operational Ex A&D 6.3% 4.6% 5.7%
U.S. 11.2% 3.3% 8.6%
International (0.7)% 6.1% 2.0%
COVID-19 Vaccine 0.4 0.2
U.S. 0.0 0.0
International 0.7 0.4
WW Adjusted Operational Ex A&D & COVID-19 Vaccine 6.7% 4.6% 5.9%
U.S. 11.2% 3.3% 8.6%
International 0.0% 6.1% 2.4%
Adjusted Operational Sales Growth
FOURTH QUARTER 2024 ACTUAL vs. 2023 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 12 of 22 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine MedTech Total
WW As Reported 4.0% 4.8% 4.3%
U.S. 9.0% 6.9% 8.3%
International (2.5)% 2.6% (0.5)%
WW Currency (1.7) (1.4) (1.6)
U.S. - - -
International (3.8) (2.8) (3.4)
WW Operational 5.7% 6.2% 5.9%
U.S. 9.0% 6.9% 8.3%
International 1.3% 5.4% 2.9%
Shockwave (1.9) (0.7)
U.S. (2.9) (1.0)
International (0.8) (0.3)
All Other Acquisitions and Divestitures (A&D) 0.1 0.4 0.2
U.S. 0.1 0.8 0.3
International 0.2 0.1 0.1
WW Adjusted Operational Ex A&D 5.8% 4.7% 5.4%
U.S. 9.1% 4.8% 7.6%
International 1.5% 4.7% 2.7%
COVID-19 Vaccine 1.8 1.1
U.S. 0.0 0.0
International 4.2 2.6
WW Adjusted Operational Ex A&D & COVID-19 Vaccine 7.6% 4.7% 6.5%
U.S. 9.1% 4.8% 7.6%
International 5.7% 4.7% 5.3%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
TWELVE MONTHS 2024 ACTUAL vs. 2023 ACTUAL
Segments

-- 13 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
INNOVATIVE MEDICINE SEGMENT (2) 2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency
IMMUNOLOGY
US 2,856	$ 3,033 -5.9% -5.9% - 11,355	$ 11,539 -1.6% -1.6% -
Intl 1,383 1,562 -11.5% -6.5% -5.0% 6,473 6,513 -0.6% 4.0% -4.6%
WW 4,238 4,595 -7.8% -6.1% -1.7% 17,828 18,052 -1.2% 0.4% -1.6%
REMICADE
US 231 294 -21.4% -21.4% - 1,009 1,143 -11.7% -11.7% -
US Exports (3) 9 35 -73.3% -73.3% - 98 147 -33.0% -33.0% -
Intl 117 100 16.5% 22.9% -6.4% 497 549 -9.5% -5.0% -4.5%
WW 359 429 -16.5% -15.0% -1.5% 1,605 1,839 -12.8% -11.4% -1.4%
SIMPONI / SIMPONI ARIA
US 262 258 1.3% 1.3% - 1,082 1,124 -3.8% -3.8% -
Intl 321 244 32.1% 44.2% -12.1% 1,108 1,073 3.3% 13.2% -9.9%
WW 583 502 16.2% 22.1% -5.9% 2,190 2,197 -0.3% 4.5% -4.8%
STELARA
US 1,699 1,786 -4.9% -4.9% - 6,720 6,966 -3.5% -3.5% -
Intl 650 967 -32.7% -29.6% -3.1% 3,641 3,892 -6.4% -3.3% -3.1%
WW 2,349 2,753 -14.7% -13.6% -1.1% 10,361 10,858 -4.6% -3.4% -1.2%
TREMFYA
US 654 657 -0.6% -0.6% - 2,443 2,147 13.7% 13.7% -
Intl 295 252 16.9% 21.7% -4.8% 1,227 999 22.8% 27.6% -4.8%
WW 949 910 4.2% 5.6% -1.4% 3,670 3,147 16.6% 18.1% -1.5%
OTHER IMMUNOLOGY
US 0 2 * * - 3 11 -74.1% -74.1% -
Intl 0 0 - - - 0 0 - - -
WW 0 2 * * * 3 11 -74.1% -74.1% -
INFECTIOUS DISEASES
US 331 353 -6.4% -6.4% - 1,354 1,500 -9.8% -9.8% -
Intl 443 498 -11.2% -9.8% -1.4% 2,042 2,918 -30.0% -29.3% -0.7%
WW 774 852 -9.2% -8.4% -0.8% 3,396 4,418 -23.1% -22.7% -0.4%
COVID-19 VACCINE
US 0 0 - - - 0 0 - - -
Intl 0 44 * * * 198 1,117 -82.4% -82.4% 0.0%
WW 0 44 * * * 198 1,117 -82.4% -82.4% 0.0%
EDURANT / rilpivirine
US 7 9 -10.1% -10.1% - 31 35 -10.0% -10.0% -
Intl 315 299 5.0% 5.6% -0.6% 1,241 1,115 11.2% 11.2% 0.0%
WW 322 307 4.6% 5.1% -0.5% 1,272 1,150 10.6% 10.6% 0.0%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 321 341 -5.8% -5.8% - 1,311 1,446 -9.4% -9.4% -
Intl 86 98 -12.9% -8.9% -4.0% 401 408 -1.7% 1.1% -2.8%
WW 407 439 -7.4% -6.5% -0.9% 1,712 1,854 -7.7% -7.1% -0.6%
OTHER INFECTIOUS DISEASES
US 1 4 -53.1% -53.1% - 11 19 -41.0% -41.0% -
Intl 43 58 -24.2% -22.4% -1.8% 203 278 -26.7% -23.9% -2.8%
WW 45 62 -26.1% -24.4% -1.7% 214 297 -27.6% -25.0% -2.6%
% Change	% Change

-- 14 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency
NEUROSCIENCE
US 1,148 1,022 12.3% 12.3% - 4,398 4,065 8.2% 8.2% -
Intl 628 780 -19.6% -16.8% -2.8% 2,718 3,076 -11.6% -7.8% -3.8%
WW 1,775 1,801 -1.5% -0.3% -1.2% 7,115 7,140 -0.4% 1.3% -1.7%
CONCERTA / Methylphenidate
US 33 39 -12.8% -12.8% - 134 230 -41.7% -41.7% -
Intl 125 142 -11.5% -7.7% -3.8% 507 554 -8.4% -4.1% -4.3%
WW 159 180 -11.7% -8.8% -2.9% 641 783 -18.1% -15.1% -3.0%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 796 733 8.6% 8.6% - 3,125 2,897 7.9% 7.9% -
Intl 267 278 -4.0% -1.8% -2.2% 1,097 1,218 -9.9% -7.1% -2.8%
WW 1,063 1,011 5.1% 5.7% -0.6% 4,222 4,115 2.6% 3.4% -0.8%
SPRAVATO
US 269 180 50.1% 50.1% - 929 589 57.8% 57.8% -
Intl 28 26 7.1% 12.5% -5.4% 148 100 48.2% 51.2% -3.0%
WW 297 206 44.6% 45.3% -0.7% 1,077 689 56.4% 56.8% -0.4%
OTHER NEUROSCIENCE
US 49 71 -31.0% -31.0% - 210 349 -39.8% -39.8% -
Intl 206 334 -38.1% -35.4% -2.7% 965 1,204 -19.8% -15.1% -4.7%
WW 255 404 -36.9% -34.6% -2.3% 1,175 1,553 -24.3% -20.7% -3.6%
ONCOLOGY
US 3,019 2,285 32.2% 32.2% - 10,854 8,462 28.3% 28.3% -
Intl 2,476 2,334 6.1% 10.6% -4.5% 9,926 9,199 7.9% 12.1% -4.2%
WW 5,497 4,618 19.0% 21.3% -2.3% 20,781 17,661 17.7% 19.8% -2.1%
CARVYKTI
US 304 145 * * - 869 469 85.2% 85.2% -
Intl 31 13 * * * 94 30 * * *
WW 334 159 * * * 963 500 92.7% 92.7% 0.0%
DARZALEX
US 1,799 1,395 28.9% 28.9% - 6,588 5,277 24.8% 24.8% -
Intl 1,285 1,155 11.3% 17.0% -5.7% 5,082 4,467 13.8% 19.1% -5.3%
WW 3,084 2,550 20.9% 23.5% -2.6% 11,670 9,744 19.8% 22.2% -2.4%
ERLEADA
US 342 287 19.0% 19.0% - 1,282 1,065 20.3% 20.3% -
Intl 442 361 22.4% 25.7% -3.3% 1,717 1,322 29.8% 32.9% -3.1%
WW 784 647 20.9% 22.7% -1.8% 2,999 2,387 25.6% 27.3% -1.7%
IMBRUVICA
US 250 255 -2.0% -2.0% - 1,020 1,051 -3.0% -3.0% -
Intl 481 533 -9.6% -6.8% -2.8% 2,018 2,214 -8.8% -6.3% -2.5%
WW 731 788 -7.2% -5.2% -2.0% 3,038 3,264 -6.9% -5.2% -1.7%
TECVAYLI
US 108 102 5.6% 5.6% - 418 334 25.3% 25.3% -
Intl 38 24 59.9% 71.6% -11.7% 131 61 * * *
WW 146 126 15.8% 18.0% -2.2% 549 395 38.8% 39.8% -1.0%
ZYTIGA / abiraterone acetate
US 9 9 -7.3% -7.3% - 34 50 -32.2% -32.2% -
Intl 127 191 -33.6% -30.7% -2.9% 597 837 -28.6% -24.6% -4.0%
WW 135 201 -32.4% -29.6% -2.8% 631 887 -28.8% -25.0% -3.8%
OTHER ONCOLOGY
US 208 90 * * - 643 215 * * -
Intl 74 58 25.5% 30.6% -5.1% 288 269 7.1% 10.4% -3.3%
WW 282 148 90.4% 92.4% -2.0% 931 484 92.5% 94.3% -1.8%
% Change	% Change

-- 15 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency
PULMONARY HYPERTENSION
US 819 733 11.6% 11.6% - 3,143 2,697 16.5% 16.5% -
Intl 274 282 -3.2% 1.2% -4.4% 1,140 1,117 2.0% 8.2% -6.2%
WW 1,092 1,017 7.4% 8.7% -1.3% 4,282 3,815 12.3% 14.1% -1.8%
OPSUMIT
US 385 368 4.8% 4.8% - 1,520 1,292 17.7% 17.7% -
Intl 160 169 -5.2% -2.5% -2.7% 664 681 -2.4% 1.1% -3.5%
WW 545 536 1.7% 2.5% -0.8% 2,184 1,973 10.7% 11.9% -1.2%
UPTRAVI
US 391 348 12.3% 12.3% - 1,511 1,326 13.9% 13.9% -
Intl 75 70 5.7% 11.2% -5.5% 307 255 20.1% 27.3% -7.2%
WW 465 419 11.2% 12.1% -0.9% 1,817 1,582 14.9% 16.1% -1.2%
OTHER PULMONARY HYPERTENSION
US 42 18 * * - 112 79 41.8% 41.8% -
Intl 40 45 -10.0% -0.4% -9.6% 169 182 -6.9% 8.2% -15.1%
WW 82 61 32.3% 39.3% -7.0% 281 260 7.9% 18.3% -10.4%
CARDIOVASCULAR / METABOLISM / OTHER
US 805 652 23.3% 23.3% - 2,866 2,906 -1.4% -1.4% -
Intl 153 185 -17.6% -15.1% -2.5% 696 765 -9.1% -7.1% -2.0%
WW 957 837 14.3% 14.8% -0.5% 3,562 3,671 -3.0% -2.6% -0.4%
XARELTO
US 676 525 28.5% 28.5% - 2,373 2,365 0.3% 0.3% -
Intl - - - - - - - - - -
WW 676 525 28.5% 28.5% - 2,373 2,365 0.3% 0.3% -
OTHER
US 130 127 1.5% 1.5% - 494 541 -8.8% -8.8% -
Intl 153 185 -17.6% -15.1% -2.5% 696 765 -9.1% -7.1% -2.0%
WW 281 312 -9.8% -8.3% -1.5% 1,189 1,306 -8.9% -7.8% -1.1%
TOTAL INNOVATIVE MEDICINE
US 8,977 8,079 11.1% 11.1% - 33,970 31,169 9.0% 9.0% -
Intl 5,355 5,643 -5.1% -1.0% -4.1% 22,994 23,590 -2.5% 1.3% -3.8%
WW 14,332	$ 13,722	$ 4.4% 6.1% -1.7% 56,964	$ 54,759 4.0% 5.7% -1.7%
See footnotes at end of schedule
% Change	% Change

-- 16 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
MEDTECH SEGMENT (2) 2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency
CARDIOVASCULAR (4)
US 1,221	$ 971 25.8% 25.8% - 4,513	$ 3,633 24.2% 24.2% -
Intl 841 698 20.6% 22.0% -1.4% 3,194 2,717 17.6% 20.9% -3.3%
WW 2,062 1,669 23.6% 24.2% -0.6% 7,707 6,350 21.4% 22.8% -1.4%
ELECTROPHYSIOLOGY
US 681 667 2.1% 2.1% - 2,738 2,458 11.4% 11.4% -
Intl 640 572 11.7% 13.3% -1.6% 2,529 2,230 13.4% 17.0% -3.6%
WW 1,321 1,239 6.6% 7.3% -0.7% 5,267 4,688 12.3% 14.0% -1.7%
ABIOMED
US 308 276 11.3% 11.3% - 1,213 1,066 13.7% 13.7% -
Intl 77 64 19.8% 21.1% -1.3% 284 240 18.2% 20.3% -2.1%
WW 384 340 12.9% 13.2% -0.3% 1,496 1,306 14.5% 14.9% -0.4%
SHOCKWAVE (5)
US 202 - * * - 442 - * * -
Intl 56 - * * - 122 - * * -
WW 258 - * * - 564 - * * -
OTHER CARDIOVASCULAR (4)
US 31 28 11.1% 11.1% - 120 109 10.7% 10.7% -
Intl 68 61 12.1% 12.3% -0.2% 260 247 5.3% 7.3% -2.0%
WW 99 89 11.8% 12.0% -0.2% 380 356 6.9% 8.4% -1.5%
ORTHOPAEDICS
US 1,460 1,425 2.4% 2.4% - 5,689 5,525 3.0% 3.0% -
Intl 856 843 1.6% 2.5% -0.9% 3,470 3,417 1.5% 3.0% -1.5%
WW 2,315 2,268 2.1% 2.5% -0.4% 9,158 8,942 2.4% 3.0% -0.6%
HIPS
US 272 266 2.5% 2.5% - 1,057 996 6.2% 6.2% -
Intl 146 132 10.6% 11.7% -1.1% 581 564 3.0% 4.6% -1.6%
WW 418 398 5.2% 5.6% -0.4% 1,638 1,560 5.0% 5.6% -0.6%
KNEES
US 238 242 -1.5% -1.5% - 922 896 2.9% 2.9% -
Intl 160 144 10.7% 11.3% -0.6% 623 559 11.3% 12.4% -1.1%
WW 398 387 3.1% 3.3% -0.2% 1,545 1,456 6.1% 6.5% -0.4%
TRAUMA
US 514 487 5.5% 5.5% - 2,013 1,949 3.3% 3.3% -
Intl 250 255 -1.9% -0.5% -1.4% 1,036 1,030 0.6% 2.1% -1.5%
WW 764 741 3.0% 3.5% -0.5% 3,049 2,979 2.3% 2.9% -0.6%
SPINE, SPORTS & OTHER
US 434 430 1.1% 1.1% - 1,696 1,684 0.7% 0.7% -
Intl 300 311 -3.6% -2.9% -0.7% 1,230 1,263 -2.6% -1.2% -1.4%
WW 735 742 -0.9% -0.6% -0.3% 2,926 2,947 -0.7% -0.1% -0.6%
% Change	% Change

-- 17 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency
SURGERY
US 1,038 1,047 -0.9% -0.9% - 4,003 4,031 -0.7% -0.7% -
Intl 1,469 1,484 -1.0% 1.4% -2.4% 5,842 6,006 -2.7% 0.6% -3.3%
WW 2,507 2,530 -0.9% 0.4% -1.3% 9,845 10,037 -1.9% 0.1% -2.0%
ADVANCED
US 478 468 2.0% 2.0% - 1,838 1,833 0.2% 0.2% -
Intl 673 698 -3.6% -1.6% -2.0% 2,650 2,837 -6.6% -3.5% -3.1%
WW 1,151 1,167 -1.4% -0.1% -1.3% 4,488 4,671 -3.9% -2.0% -1.9%
GENERAL
US 560 579 -3.1% -3.1% - 2,165 2,198 -1.5% -1.5% -
Intl 795 785 1.4% 4.0% -2.6% 3,192 3,168 0.8% 4.3% -3.5%
WW 1,357 1,364 -0.5% 1.0% -1.5% 5,358 5,366 -0.2% 2.0% -2.2%
VISION
US 509 487 4.5% 4.5% - 2,128 2,086 2.0% 2.0% -
Intl 794 721 10.2% 12.2% -2.0% 3,018 2,986 1.1% 3.7% -2.6%
WW 1,303 1,208 7.9% 9.1% -1.2% 5,146 5,072 1.5% 3.0% -1.5%
CONTACT LENSES / OTHER
US 396 374 6.0% 6.0% - 1,684 1,626 3.6% 3.6% -
Intl 541 508 6.4% 8.5% -2.1% 2,049 2,076 -1.3% 1.8% -3.1%
WW 937 882 6.3% 7.4% -1.1% 3,733 3,702 0.8% 2.6% -1.8%
SURGICAL
US 113 114 -0.4% -0.4% - 444 460 -3.4% -3.4% -
Intl 252 212 19.3% 21.1% -1.8% 969 910 6.5% 8.2% -1.7%
WW 365 326 12.4% 13.6% -1.2% 1,413 1,370 3.2% 4.3% -1.1%
TOTAL MEDTECH
US 4,227 3,930 7.6% 7.6% - 16,332 15,275 6.9% 6.9% -
Intl 3,961 3,743 5.8% 7.6% -1.8% 15,525 15,125 2.6% 5.4% -2.8%
WW 8,188	$ 7,673	$ 6.7% 7.6% -0.9% 31,857	$ 30,400 4.8% 6.2% -1.4%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Reported as U.S. sales
(4) Previously referred to as Interventional Solutions
(5) Acquired on May 31, 2024
% Change
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely
% Change

-- 18 of 22 --

2024 2023 Total Operations Currency 2024 2023 Total Operations Currency
Innovative Medicine
U.S. 8,977	$ 8,079 11.1 11.1 - 33,970	$ 31,169 9.0 9.0 -
International 5,355 5,643 (5.1) (1.0) (4.1) 22,994 23,590 (2.5) 1.3 (3.8)
Worldwide 14,332 13,722 4.4 6.1 (1.7) 56,964 54,759 4.0 5.7 (1.7)
COVID-19 Vaccine
U.S. - - - - - - - - - -
International - 44 * * * 198 1,117 (82.4) (82.4) 0.0
Worldwide - 44 * * * 198 1,117 (82.4) (82.4) 0.0
Innovative Medicine excluding COVID-19 Vaccine
U.S. 8,977 8,079 11.1 11.1 - 33,970 31,169 9.0 9.0 -
International 5,355 5,599 (4.4) (0.3) (4.1) 22,796 22,473 1.4 5.5 (4.1)
Worldwide 14,332 13,678 4.8 6.5 (1.7) 56,766 53,642 5.8 7.5 (1.7)
Worldwide
U.S. 13,204 12,009 10.0 10.0 - 50,302 46,444 8.3 8.3 -
International 9,316 9,386 (0.7) 2.5 (3.2) 38,519 38,715 (0.5) 2.9 (3.4)
Worldwide 22,520 21,395 5.3 6.7 (1.4) 88,821 85,159 4.3 5.9 (1.6)
COVID-19 Vaccine
U.S. - - - - - - - - - -
International - 44 * * * 198 1,117 (82.4) (82.4) 0.0
Worldwide - 44 * * * 198 1,117 (82.4) (82.4) 0.0
Worldwide
U.S. 13,204 12,009 10.0 10.0 - 50,302 46,444 8.3 8.3 -
International 9,316 9,342 (0.3) 2.9 (3.2) 38,321 37,598 1.9 5.5 (3.6)
Worldwide excluding COVID-19 Vaccine 22,520	$ 21,351 5.5 6.9 (1.4) 88,623	$ 84,042 5.5 7.0 (1.5)
Europe 4,921	$ 4,962 (0.8) (0.2) (0.6) 20,212	$ 20,410 (1.0) (0.6) (0.4)
Europe COVID-19 Vaccine Sales - 44 * * * 198 1,117 (82.4) (82.4) 0.0
Europe excluding COVID-19 Vaccine Sales 4,921	$ 4,918 0.1 0.7 (0.6) 20,014	$ 19,293 3.7 4.1 (0.4)
* Percentage greater than 100% or not meaningful
Percent Change
FOURTH QUARTER
Percent Change
Supplemental Sales Information (Unaudited)
(Dollars in Millions)
TWELVE MONTHS

-- 19 of 22 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2024 2023 2024 2023 2024 2023 2024 2023
Reported Income Before Tax by Segment From Continuing Operations $ 4,009 4,238 72 404 (194) 184 3,887 4,826
% to Sales 28.0% 30.9% 0.9% 5.3% -0.9% 0.9% 17.3% 22.6%
Intangible asset amortization expense 685 747 486 401 - - 1,171 1,148
In-process research and development impairments 17 - - 58 - - 17 58
Litigation related (41) 17 (29) 149 54 - (16) 166
Loss/(gain) on securities (50) (112) (18) (59) - (264) (68) (435)
Restructuring related 2 55 60 84 - - 62 139
Acquisition, integration and divestiture related 12 175 268 62 18 - 298 237
Medical Device Regulation - - 47 88 - - 47 88
COVID-19 Vaccine related costs 23 10 - - - - 23 10
Adjusted Income Before Tax by Segment From Continuing Operations $ 4,657 5,130 886 1,187 (122) (80) 5,421 6,237
% to Sales 32.5% 37.4% 10.8% 15.5% -0.5% -0.4% 24.1% 29.2%
*Estimated as of 1/22/2025
As Reported Research and development expense** $ 3,698 3,357 1,600 1,123 5,298 4,480
% to Sales 25.8% 24.5% 19.5% 14.6% 23.5% 20.9%
**Includes the following Acquired IPR&D:
Laminar - Q4 2023 390 390
V-Wave - Q4 2024 540 540
Total 540 390 540 390
Q4 QTD - Income Before Tax* and Research & Development Expense by Segment
Dollars in Millions
Innovative Medicine MedTech Unallocated Worldwide Total

-- 20 of 22 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2024 2023 2024 2023 2024 2023 2024 2023
Reported Income Before Tax by Segment From Continuing Operations $ 18,919 18,246 3,740 4,669 (5,972) (7,853) 16,687 15,062
% to Sales 33.2% 33.3% 11.7% 15.4% -6.7% -9.2% 18.8% 17.7%
Intangible asset amortization expense 2,772 2,983 1,754 1,549 - - 4,526 4,532
In-process research and development impairments 211 206 - 107 - - 211 313
Litigation related 358 (108) (14) 190 5,106 7,070 5,450 7,152
Loss/(gain) on securities (76) 362 30 (102) 352 381 306 641
Restructuring related 102 479 167 319 - - 269 798
Acquisition, integration and divestiture related 66 175 1,015 164 145 - 1,226 339
Medical Device Regulation - - 204 311 - - 204 311
COVID-19 Vaccine related costs 100 663 - - - - 100 663
Adjusted Income Before Tax by Segment From Continuing Operations $ 22,452 23,006 6,896 7,207 (369) (402) 28,979 29,811
% to Sales 39.4% 42.0% 21.6% 23.7% -0.4% -0.5% 32.6% 35.0%
*Estimated as of 1/22/2025
As Reported Research and development expense** $ 13,529 11,963 3,703 3,122 17,232 15,085
% to Sales 23.8% 21.8% 11.6% 10.3% 19.4% 17.7%
**Includes the following Acquired IPR&D:
Laminar - Q4 2023 390 390
Yellow Jersey (NM26 bispecific antibody) - Q3 2024 1,250 1,250
V-Wave -Q4 2024 540 540
Total 1,250 540 390 1,790 390
Q4 YTD - Income Before Tax* and Research & Development Expense by Segment
Dollars in Millions
Innovative Medicine MedTech Unallocated Worldwide Total

-- 21 of 22 --

Fourth Quarter
Dec. 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Medical Device
Regulation
Fourth Quarter
Dec. 29, 2024
Non-GAAP
Cost of products sold 7,128	$ (1,162) (20) (153) (18) - - 5,775
Selling, marketing and admin expenses 6,453 (4) 6,449
Research and development expense 5,298 - (25) (6) 5,267
Other (Income) / Expense (161) (9) 16 - (145) 68 (17) (248)
In-process research and development impairments 17 (17) - -
Restructuring 42 (42) -
Provision for taxes on income 456 171 (158) 4 3 80 (34) 9 5 (61) 475
Net Earnings from Continuing Operations 3,431 1,000 142 13 59 218 (34) 38 18 61 4,946
Fourth Quarter
Dec. 31, 2023
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Medical Device
Regulation
Fourth Quarter
Dec. 31, 2023
Non-GAAP
Cost of products sold 6,798	$ (1,131) (83) (42) (12) - 5,530
Selling, marketing and admin expenses 5,810 (8) 5,802
Research and development expense 4,480 (16) (38) (1) 4,425
Other (Income) / Expense (421) (17) (166) - (221) 435 3 (387)
In-process research and development impairments 58 (58) -
Restructuring 56 (56) -
Provision for taxes on income 694 175 (134) 13 16 30 (191) 16 - 56 675
Net Earnings from Continuing Operations 4,132 973 300 45 123 207 (244) 72 10 (56) 5,562
Twelve Months
Dec. 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Medical Device
Regulation
Twelve Months
Dec. 29, 2024
Non-GAAP
Cost of products sold 27,471	$ (4,517) (35) (359) (84) (8) 22,468
Selling, marketing and admin expenses 22,869 (16) - 22,853
Research and development expense 17,232 (69) (104) (25) 17,034
Other (Income) / Expense 4,694 (9) (5,450) - (798) (306) (67) (1,936)
In-process research and development impairments 211 (211) - - - - -
Restructuring 234 (234) -
Provision for taxes on income 2,621 644 1,066 47 45 302 (29) 38 22 (19) 4,737
Net Earnings from Continuing Operations 14,066 3,882 4,384 164 224 924 335 166 78 19 24,242
Twelve Months
Dec. 31, 2023
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Medical Device
Regulation
Twelve Months
Dec. 31, 2023
Non-GAAP
Cost of products sold 26,553	$ (4,511) (309) (133) (189) 21,411
Selling, marketing and admin expenses 21,512 (29) 21,483
Research and development expense 15,085 (32) (149) (99) 14,805
Other (Income) / Expense 6,634 (21) (7,152) - (307) (641) (375) (1,862)
In-process research and development impairments 313 (313) - -
Restructuring 489 (489) -
Provision for taxes on income 1,736 707 1,505 70 157 52 (9) 57 155 (28) 4,402
Net Earnings from Continuing Operations 13,326 3,825 5,647 243 641 287 650 254 508 28 25,409
In-process
research and
development
impairments
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
In-process
research and
development
impairments
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Year to Date
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date
In-process
research and
development
impairments
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
In-process
research and
development
impairments
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related

-- 22 of 22 --